🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

RecruitingPhase 4Ages 40 Years - 75 YearsAllQilu Hospital of Shandong University
NCT06699420 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; * Coronary normal or stenosis \< 20%; * Ischemic depression in ST segment during resting or exercise; * Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0; * Subjects or their guardians agreed to participate in this study. Exclusion Criteria: * Previous myocardial infarction or PCI or CABG treatment; * A history of heart failure; * Severe arrhythmia; * Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm; * Familial hypercholesterolemia; * Takayasu arteritis, Kawasaki disease or coronary artery malformation; * Pregnant or nursing, or having the intention to give birth within one year; * Hepatic or renal dysfunction; * Allergic to contrast agents or traditional Chinese medicines; * Patients who participated in clinical research of other drugs within 3 months before being selected.
💊

What it tests

  • Qishenyiqi dripping pills 1 bag, three times a day
  • Placebo 1 bag, three times a day
📍

Where

3 sites
Qianfoshan Hospital, Shandong University
Jinan, China
Qilu Hospital of Shandong University
Jinan, China
Jinan Central Hospital Affiliated to Shandong First Medical University
Jinan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy